# Efficacy and Safety of Dalbavancin As Suppressive Therapy

> **NCT06899906** · — · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 33 (estimated)

## Conditions studied

- Efficacy and Safety of Dalbavancin
- In Subjects Who Received SAT with DAL
- For Acute or Chronic Infections Between July 2019 and December 2024

## Interventions

- **OTHER:** Determine patient demographic and clinical characteristics at baseline

## Key facts

- **NCT ID:** NCT06899906
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899906, "Efficacy and Safety of Dalbavancin As Suppressive Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06899906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*